ILT4 in the Tumor Immune Microenvironment: Regulatory Roles and Implications for Immunotherapy

Literature Information

This article dissects cutting-edge research on immunoglobulin-like transcript 4 (ILT4, also known as CD85d or LILRB2), a key inhibitory receptor in the immunoglobulin superfamily, unraveling its multifaceted regulatory roles in the tumor immune microenvironment, immunotherapy resistance, and potential as a therapeutic target. The research highlights the critical application value of ILT4-specific detection tools in advancing tumor immunology research and translational medicine, with the Rabbit Anti-Human ILT4 (CD85d) Antibody (Cat. No.: S0B0867)—independently developed and produced by ANT BIO PTE. LTD.—serving as an indispensable core research tool for ILT4 detection, localization, interaction analysis, and functional validation. This study deepens the understanding of ILT4 as a novel immune checkpoint and lays a solid foundation for developing combination immunotherapy strategies to overcome treatment resistance, with ANT BIO’s high-performance antibody empowering every step of mechanistic exploration and preclinical development.

Research Background

Tumor immunotherapy, particularly immune checkpoint inhibitors targeting PD-1/PD-L1, has revolutionized the treatment landscape for various malignancies. However, the emergence of primary and acquired resistance, as well as limited response rates in certain patient populations, remains a major clinical challenge. The tumor immune microenvironment (TIME)—a complex ecosystem comprising tumor cells, immune cells, stromal cells, and soluble factors—plays a pivotal role in tumor immune evasion and immunotherapy efficacy. Inhibitory receptors expressed on immune cells are key regulators of the TIME, and their abnormal activation often contributes to immune suppression and treatment resistance.

ILT4, a member of the immunoglobulin superfamily, is predominantly expressed on myeloid cells (monocytes, macrophages, dendritic cells, granulocytes) and functions as a critical inhibitory receptor. Through its extracellular immunoglobulin-like domains, ILT4 binds to a broad range of ligands, including classical and non-classical MHC class I molecules, complement components, and angiopoietin-like proteins. Its intracellular segment contains immunoreceptor tyrosine-based inhibitory motifs (ITIMs) that recruit phosphatases such as SHP-1 and SHP-2, transmitting inhibitory signals to regulate immune cell activation and function. Mounting evidence indicates that ILT4 is frequently upregulated in the TIME, where it promotes immune suppression, facilitates tumor evasion, and is associated with poor prognosis and immunotherapy resistance. The development of high-specificity, high-affinity ILT4 detection tools is therefore essential for dissecting its biological functions and developing targeted therapeutic strategies—an unmet need addressed by ANT BIO PTE. LTD.’s Rabbit Anti-Human ILT4 (CD85d) Antibody.

Research Rationale

Deciphering ILT4’s Basic Structure, Ligand Interactions, and Core Functions

The research first set out to systematically characterize ILT4’s molecular structure, ligand-binding profile, and fundamental biological functions, hypothesizing that its broad ligand specificity and inhibitory signaling capacity enable it to regulate diverse physiological and pathological processes, including tumor immune evasion. The research team aimed to map ILT4’s key structural domains (extracellular ligand-binding regions, intracellular ITIMs) and clarify how ligand binding triggers downstream inhibitory signaling cascades.

Elucidating ILT4’s Regulatory Roles in the Tumor Immune Microenvironment

A core research objective was to dissect ILT4’s cell-type-specific functions in the TIME, focusing on its ability to modulate myeloid cell function, T cell activity, and the overall immune-suppressive landscape. The research designed a series of in vitro and in vivo experiments to investigate how ILT4 upregulation on tumor-infiltrating myeloid cells inhibits antigen presentation, promotes M2 macrophage polarization, expands regulatory T cells, and suppresses effector T cell function—collectively fostering a tumor-permissive microenvironment.

Investigating ILT4’s Role in Immunotherapy Resistance and Combination Therapy Potential

The research also aimed to explore the causal link between ILT4 signaling and resistance to PD-1/PD-L1 inhibitors, hypothesizing that ILT4-mediated immune suppression weakens the efficacy of checkpoint blockade. It sought to validate whether targeting ILT4 can reverse immunotherapy resistance and synergize with PD-1/PD-L1 inhibitors to enhance anti-tumor immunity, providing a rationale for combination immunotherapy strategies.

Defining the Application Value of ILT4-Specific Antibodies in Tumor Research and Translation

Finally, the research set out to establish the multifaceted application value of rabbit anti-human ILT4 (CD85d) antibodies in basic and translational tumor immunology research. It aimed to demonstrate the antibody’s utility in ILT4 detection, localization, interaction analysis, and functional blockade, positioning it as an indispensable tool for mechanistic studies, patient stratification, and preclinical evaluation of ILT4-targeted therapeutics.

Research Outcomes

This research systematically unravels ILT4’s regulatory roles in the tumor immune microenvironment and immunotherapy resistance, yielding a series of key findings that advance the understanding of tumor immune evasion and validate the critical application value of ILT4-specific antibodies:

1. ILT4 possesses a unique structural architecture and broad ligand-binding capacity: ILT4 is an inhibitory receptor with extracellular immunoglobulin-like domains (for ligand binding) and intracellular ITIMs (for inhibitory signal transduction). Its ligands include classical MHC class I molecules (HLA-A, HLA-B), non-classical MHC class I molecules (HLA-G), MHC-like molecules (CD1d), complement components (C4d, C3d, C4b, C3b, iC3b), angiopoietin-like proteins, β-amyloid proteins, and semaphorin 4A. This broad ligand specificity enables ILT4 to regulate diverse processes, including pregnancy-related immune tolerance, cardiovascular disease, and tumor immune evasion.
2. ILT4 drives immune suppression in the tumor immune microenvironment: ILT4 is frequently upregulated in the TIME, where it promotes immune evasion through multiple mechanisms: (1) Tumor cells or stromal cells express ILT4 ligands (e.g., HLA-G), activating ILT4 on tumor-infiltrating myeloid cells, thereby inhibiting their antigen-presenting function and pro-inflammatory cytokine secretion; (2) ILT4 signaling induces regulatory T cell expansion, suppresses effector T cell activity, and promotes M2-type tumor-associated macrophage polarization, constructing an immune-suppressive TIME favorable for tumor growth; (3) ILT4 regulates pathways such as angiopoietin-like proteins to promote tumor angiogenesis and metastasis. High ILT4 expression is significantly correlated with tumor progression, metastasis, and poor prognosis in various solid tumors and hematologic malignancies, highlighting its potential as a tumor biomarker and therapeutic target.
3. ILT4 is a key mediator of immunotherapy resistance: Abnormal activation of the ILT4 signaling pathway is closely associated with resistance to PD-1/PD-L1 inhibitors. In the TIME, ILT4 impairs immunotherapy efficacy through multiple mechanisms, including inhibiting dendritic cell maturation, suppressing T cell activation, and promoting the accumulation of immune-suppressive cells. Preclinical studies confirm that blocking ILT4 signaling reverses the immune-suppressive functions of tumor-associated macrophages, enhances the infiltration and activity of cytotoxic T cells, and synergizes with PD-1/PD-L1 inhibitors to exert potent anti-tumor effects. Several ILT4-targeting antibody drugs have entered preclinical or early clinical development, providing new directions for combination immunotherapy.
4. ILT4-targeted therapy faces unique challenges but holds great promise: Despite its therapeutic potential, ILT4-targeted strategies encounter several hurdles: (1) ILT4 plays a critical role in maintaining immune homeostasis, so complete blockade may trigger autoimmune or inflammatory adverse effects, requiring precise modulation; (2) ILT4 expression patterns vary across tumor types and individuals, necessitating reliable biomarkers for patient stratification; (3) The optimal combination of ILT4-targeted drugs with existing therapies requires further preclinical and clinical validation. With deepening understanding of ILT4’s signaling network, future drug development will become more precise, and advances in research tools such as ILT4-specific antibodies will accelerate clinical translation.

Product Empowerment: The Pivotal Role of ANT BIO’s Rabbit Anti-Human ILT4 (CD85d) Antibody in Tumor Research

The Rabbit Anti-Human ILT4 (CD85d) Antibody (Cat. No.: S0B0867) independently developed and produced by ANT BIO PTE. LTD. is an indispensable core research tool that underpins all aspects of ILT4-related tumor immunology research, with its exceptional performance and versatility empowering mechanistic exploration, preclinical development, and translational research:

1. High specificity and functional recognition enable precise ILT4 detection: The antibody accurately recognizes human ILT4 (CD85d/LILRB2) with high specificity for myeloid cells (monocytes, macrophages, dendritic cells), ensuring reliable identification and typing of ILT4-positive cells in complex biological samples (tumor tissues, peripheral blood). Some antibody clones also possess ligand-binding blockade capabilities, enabling functional studies to assess the impact of ILT4 inhibition on immune cell activity.
2. Superior affinity and sensitivity for endogenous ILT4 detection: The antibody exhibits high binding affinity for ILT4, enabling sensitive detection of endogenous ILT4 protein levels in primary cells, cell lines, and formalin-fixed paraffin-embedded (FFPE) tissues without the need for overexpression. This allows for the accurate quantification of ILT4 expression changes in the TIME under physiological and pathological conditions, providing critical data for studying its regulatory mechanisms in tumor immune evasion.
3. Validated performance across multiple key experimental platforms: Rigorously validated for use in flow cytometry, immunohistochemistry, and co-immunoprecipitation—three core techniques in tumor immunology research—the antibody delivers consistent, reliable results across different experimental approaches:
• Flow cytometry: Enables quantitative detection of the proportion and phenotype of ILT4-positive immune cells in tumor tissues or peripheral blood.
• Immunohistochemistry: Facilitates spatial analysis of ILT4 distribution in the TIME, clarifying its localization on myeloid cells and interaction with tumor cells.
• Co-immunoprecipitation: Supports the exploration of protein-protein interactions between ILT4 and downstream signaling molecules (e.g., SHP-1, SHP-2), dissecting inhibitory signaling cascades.
4. Excellent batch consistency supports long-term and collaborative research: Manufactured under strict quality control standards with standardized immunogen design, immune serum management, and purification processes, the antibody exhibits minimal inter-batch variation. This ensures the reproducibility of experimental results across different research batches, laboratories, and multi-center studies—critical for longitudinal research on tumor progression and preclinical evaluation of ILT4-targeted therapeutics.
5. Broad application value in basic and translational research: The antibody’s utility extends across the entire research and development pipeline:
• Basic research: Enables the construction of ILT4-overexpressing or knockdown cell models to study its role in tumor development; supports the analysis of ILT4’s regulatory networks in the TIME.
• Translational research: Assists in evaluating the efficacy of ILT4-targeted therapeutics by monitoring changes in ILT4 expression in the TIME before and after treatment; facilitates patient stratification to identify populations likely to benefit from ILT4-targeted therapy; explores regulatory crosstalk between ILT4 and other immune checkpoints to optimize combination therapy strategies.
6. Comprehensive technical support optimizes experimental success: ANT BIO PTE. LTD. provides full technical documentation for the antibody, including specificity validation data, optimized experimental protocols for all supported platforms, and professional technical consultation. This comprehensive support lowers the technical barrier to using the antibody, ensuring researchers can obtain accurate and reliable results even for complex samples such as tumor tissues and primary immune cells.

ANT BIO PTE. LTD.’s Rabbit Anti-Human ILT4 (CD85d) Antibody is a high-performance research tool engineered for the rigorous demands of tumor immunology research. Its exceptional specificity, affinity, cross-platform performance, and batch consistency make it the gold-standard detection tool for ILT4, empowering groundbreaking research into the molecular mechanisms of tumor immune evasion and the development of novel combination immunotherapy strategies to overcome treatment resistance.

Related Product List

All products are independently developed and produced by ANT BIO PTE. LTD., providing high-performance research tools for ILT4-related research in tumor immunology, myeloid cell biology, and immunotherapy development:

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.

Disclaimer

This article was partially created with the assistance of artificial intelligence. If any content involves copyright or intellectual property issues, please inform us, and we promise to verify and remove it immediately.